CBD, SCCS and ECHA: Is the EU Cosmetic Market Approaching a Regulatory Turning Point?
The European cosmetics industry is navigating a critical period of regulatory uncertainty surrounding cannabidiol (CBD), as two conflicting scientific assessments threaten to reshape the market for CBD-containing beauty and personal care products. In April 2026, the Scientific Committee on Consumer Safety (SCCS) published its final opinion concluding that CBD is safe for use in cosmetic products at concentrations up to 0.19%, provided tetrahydrocannabinol (THC) impurities remain below 0.00025% [1]. This risk-based assessment, conducted according to established SCCS testing guidelines [2], applies to both dermal and oral cosmetic applications and represents the first comprehensive EU-level safety evaluation for CBD in cosmetics, offering a clear regulatory pathway for manufacturers who have invested in CBD formulations ranging from skincare serums to lip balms.
However, a parallel regulatory process threatens to undermine this positive assessment. In 2025, France’s Agency for Food, Environmental and Occupational Health & Safety (ANSES) proposed that CBD be classified as a Category 2 reproductive toxicant under the EU’s Classification, Labelling and Packaging (CLP) Regulation [3], citing concerns that it may damage the unborn child and pose risks during breastfeeding. If the European Chemicals Agency’s Risk Assessment Committee (RAC) adopts this hazard classification and the European Commission implements it through delegated legislation, CBD would face automatic prohibition under Article 15 of Regulation (EC) No 1223/2009 on cosmetic products [4], which bans substances classified as carcinogenic, mutagenic, or toxic to reproduction (CMR) categories 1A, 1B, or 2.
This creates a regulatory paradox: a substance deemed safe at defined exposure levels by the EU’s own scientific advisory body could simultaneously be banned based on intrinsic hazard properties identified in toxicological studies, regardless of actual consumer exposure in finished cosmetic products. The tension reflects a fundamental difference between risk assessment, which considers both hazard and exposure, and hazard classification under the CLP Regulation [3], which focuses solely on intrinsic properties. This divergence is not unprecedented in EU chemicals regulation, where the interaction between REACH [5], CLP, and sector-specific legislation can produce conflicting outcomes, but it is particularly acute for CBD given the substantial commercial investments already made in this ingredient category.
For cosmetic businesses, the implications are significant. Companies currently marketing CBD products within the SCCS safe limits should monitor the ECHA RAC’s evaluation of the ANSES proposal closely. The RAC opinion, expected in the coming months, will determine whether CBD receives harmonised CMR classification. If classification proceeds, industry stakeholders will need to engage rapidly in the consultation process and potentially seek derogations under Article 15’s limited exemption provisions [4], though these are rarely granted for CMR substances in cosmetics. The situation also highlights broader supply chain vulnerabilities, as manufacturers must ensure rigorous analytical testing to verify THC levels remain below the stringent 0.00025% threshold set by SCCS [1], requiring robust supplier qualification, batch testing protocols, and comprehensive documentation to demonstrate compliance with both the positive SCCS opinion and general cosmetic safety obligations.
Cosmetic businesses should immediately conduct a portfolio review of all CBD-containing products to confirm concentrations align with SCCS limits, establish monitoring systems to track the ECHA RAC opinion and subsequent Commission decisions, and prepare contingency plans for potential reformulation or market withdrawal if CMR classification proceeds.
References
[1] Scientific Committee on Consumer Safety (SCCS). (2026). Opinion on Cannabidiol (CBD) (SCCS/1685/25). European Commission. https://health.ec.europa.eu/scientific-committees/scientific-committee-consumer-safety-sccs_en
[2] Scientific Committee on Consumer Safety (SCCS). (2018). Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation, 10th Revision (SCCS/1602/18). European Commission.
[3] European Parliament and Council. (2008). Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures (CLP Regulation). Official Journal of the European Union, L 353/1.
[4] European Parliament and Council. (2009). Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. Official Journal of the European Union, L 342/59.
[5] European Parliament and Council. (2006). Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). Official Journal of the European Union, L 396/1.